The effect of diltiazem on coronary thrombosis in the conscious canine

Area of Science:

• Cardiovascular Pharmacology
• Thrombosis Research
• Antiplatelet Agent Evaluation

Background:

• Coronary thrombosis is a critical factor in myocardial infarction.
• Evaluating antithrombotic agents requires robust in vivo models.
• Diltiazem is a calcium channel blocker with potential cardiovascular effects.

Purpose of the Study:

• To assess the efficacy of diltiazem in a canine model of coronary thrombosis.
• To determine if diltiazem affects thrombus development, infarct size, or arrhythmias.
• To evaluate the correlation between ex vivo platelet aggregation and in vivo antithrombotic activity.

Main Methods:

• Conscious canine model induced with coronary thrombosis.
• Intravenous administration of diltiazem (loading dose and maintenance).
• Measurement of thrombus wet weight, left ventricular infarct size, and ventricular arrhythmias.
• Ex vivo platelet aggregation assays.

Main Results:

• Diltiazem showed no significant effect on thrombus wet weight.
• Left ventricular infarct size was not significantly altered by diltiazem.
• Frequency of ventricular arrhythmias remained unchanged.
• Ex vivo platelet aggregation was not significantly inhibited by diltiazem.

Conclusions:

• Diltiazem lacks significant antithrombotic effects in this in vivo canine model.
• In vitro or ex vivo platelet aggregation studies may not accurately predict in vivo efficacy.
• Concomitant in vivo thrombosis studies are crucial for evaluating potential antithrombotic agents.